137 related articles for article (PubMed ID: 38324486)
1. Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
Tovar Vetencourt A; Sayed-Ahmed I; Gomez J; Chen H; Agostini B; Carroll K; Parry T; Krishnan S; Sabater AL
N Engl J Med; 2024 Feb; 390(6):530-535. PubMed ID: 38324486
[TBL] [Abstract][Full Text] [Related]
2. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.
Paller AS; Guide SV; Ayala D; Gonzalez ME; Lucky AW; Bagci IS; Marinkovich MP
J Dermatolog Treat; 2024 Dec; 35(1):2350232. PubMed ID: 38724041
[TBL] [Abstract][Full Text] [Related]
3. Beremagene Geperpavec: First Approval.
Dhillon S
Drugs; 2023 Aug; 83(12):1131-1135. PubMed ID: 37432558
[TBL] [Abstract][Full Text] [Related]
4. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
5. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
[TBL] [Abstract][Full Text] [Related]
6. Improved erythema and decreased blister formation in dominant dystrophic epidermolysis bullosa following treatment with pulsed dye laser.
Garza-Mayers AC; Su KA; Wiss K
Pediatr Dermatol; 2022 Nov; 39(6):1005-1006. PubMed ID: 36063122
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Epstein AL; Haag-Molkenteller C
Cell; 2023 Aug; 186(17):3523-3523.e1. PubMed ID: 37595560
[TBL] [Abstract][Full Text] [Related]
8. A Case Report of an Infant with Autosomal Recessive Dystrophic Epidermolysis Bullosa: COL7A1 Gene Mutations at C2005T and G7922A.
Liu J; Wang L
Acta Dermatovenerol Croat; 2021 Dec; 29(3):164-166. PubMed ID: 34990346
[TBL] [Abstract][Full Text] [Related]
9. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K
Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783
[TBL] [Abstract][Full Text] [Related]
10. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.
Perdoni C; Osborn MJ; Tolar J
Transl Res; 2016 Feb; 168():50-58. PubMed ID: 26073463
[TBL] [Abstract][Full Text] [Related]
11. Esophageal stenosis in childhood: dystrophic epidermolysis bullosa without skin blistering due to collagen VII mutations.
Zimmer KP; Schumann H; Mecklenbeck S; Bruckner-Tuderman L
Gastroenterology; 2002 Jan; 122(1):220-5. PubMed ID: 11781296
[TBL] [Abstract][Full Text] [Related]
12. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.
Doolan BJ; McGrath JA; Mellerio JE
Br J Dermatol; 2024 Feb; 190(3):340-342. PubMed ID: 37936299
[No Abstract] [Full Text] [Related]
13. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
14. Coinheritance of 2 New Potentially Damaging Heterozygous COL7A1 Variants in a Family With Autosomal Dominant Epidermolysis Bullosa Pruriginosa.
Hale GI; Cohen MC; Quarrell OW; McGrath JA; Messenger AG
Pediatr Dev Pathol; 2018; 21(6):580-584. PubMed ID: 29504492
[TBL] [Abstract][Full Text] [Related]
15. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
Nyström A; Buttgereit J; Bader M; Shmidt T; Ozcelik C; Hausser I; Bruckner-Tuderman L; Kern JS
PLoS One; 2013; 8(5):e64243. PubMed ID: 23717576
[TBL] [Abstract][Full Text] [Related]
16. Identical COL71A1 heterozygous mutations resulting in different dystrophic epidermolysis bullosa phenotypes.
Knöpfel N; Noguera-Morel L; Hernández-Martin A; García-Martin A; García M; Mencía Á; Pedrero RM; de Lucas R; Escámez MJ; Torrelo A
Pediatr Dermatol; 2018 Mar; 35(2):e94-e98. PubMed ID: 29272047
[TBL] [Abstract][Full Text] [Related]
17. siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa.
Pendaries V; Gasc G; Titeux M; Tonasso L; Mejía JE; Hovnanian A
J Invest Dermatol; 2012 Jun; 132(6):1741-3. PubMed ID: 22336946
[No Abstract] [Full Text] [Related]
18. Dystrophic Epidermolysis Bullosa.
Yadav RS; Jayswal A; Shrestha S; Gupta SK; Paudel U
JNMA J Nepal Med Assoc; 2018; 56(213):879-882. PubMed ID: 31065125
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L; Greiser U; Wang W
Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
[TBL] [Abstract][Full Text] [Related]
20. Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts.
Villavisanis DF; Perrault DP; Kiani SN; Cholok D; Fox PM
J Hand Surg Am; 2024 May; 49(5):472-480. PubMed ID: 38085193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
